SK404491A3 - Tricyclic lactam compounds, pharmaceutical compositions comprising same and their use - Google Patents

Tricyclic lactam compounds, pharmaceutical compositions comprising same and their use Download PDF

Info

Publication number: SK404491A3
Authority: SK; Slovakia
Prior art keywords: methyl; alkyl; tetrahydro; pyrido; imidazol
Prior art date: 1987-09-03

Application number

SK4044-91A

Other languages

English (en)

Slovak (sk)

Inventor

Ian Harold Coates

Alexander William Oxford

Peter Charles North

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-09-03

Filing date

1991-12-23

Publication date

2000-12-11

1987-09-03 Priority claimed from GB878720695A external-priority patent/GB8720695D0/en

1988-08-15 Priority claimed from GB888819382A external-priority patent/GB8819382D0/en

1991-12-23 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2000-12-11 Publication of SK404491A3 publication Critical patent/SK404491A3/sk

Links

-1 lactam compounds Chemical class 0.000 title claims abstract description 70
239000008194 pharmaceutical composition Substances 0.000 title claims description 8
150000001875 compounds Chemical class 0.000 claims abstract description 206
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract description 30
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 28
150000003839 salts Chemical class 0.000 claims abstract description 28
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 18
239000012453 solvate Substances 0.000 claims abstract description 17
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims abstract description 10
125000005843 halogen group Chemical group 0.000 claims abstract description 10
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 6
HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims abstract description 4
208000019901 Anxiety disease Diseases 0.000 claims abstract description 3
230000036506 anxiety Effects 0.000 claims abstract description 3
125000002883 imidazolyl group Chemical group 0.000 claims abstract description 3
125000000217 alkyl group Chemical group 0.000 claims description 56
229910052757 nitrogen Inorganic materials 0.000 claims description 56
229910052739 hydrogen Inorganic materials 0.000 claims description 40
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 38
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 33
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 33
238000000034 method Methods 0.000 claims description 31
239000001257 hydrogen Substances 0.000 claims description 29
239000004480 active ingredient Substances 0.000 claims description 27
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 25
JSWZEAMFRNKZNL-UHFFFAOYSA-N alosetron Chemical compound N1C=NC(CN2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)=C1C JSWZEAMFRNKZNL-UHFFFAOYSA-N 0.000 claims description 18
125000003342 alkenyl group Chemical group 0.000 claims description 15
229910052799 carbon Inorganic materials 0.000 claims description 13
125000000304 alkynyl group Chemical group 0.000 claims description 9
125000000753 cycloalkyl group Chemical group 0.000 claims description 7
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 5
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 4
125000003545 alkoxy group Chemical group 0.000 claims description 4
125000005431 alkyl carboxamide group Chemical group 0.000 claims description 3
150000002688 maleic acid derivatives Chemical class 0.000 claims description 3
229910019142 PO4 Inorganic materials 0.000 claims description 2
125000005596 alkyl carboxamido group Chemical group 0.000 claims description 2
125000005228 aryl sulfonate group Chemical group 0.000 claims description 2
238000007911 parenteral administration Methods 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
201000000980 schizophrenia Diseases 0.000 claims description 2
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
NRZSWYSJFMDDAN-UHFFFAOYSA-N 2-[(5-methyl-1h-imidazol-4-yl)methyl]-5-prop-2-ynyl-3,4-dihydropyrido[4,3-b]indol-1-one Chemical compound N1C=NC(CN2C(C3=C(N(C4=CC=CC=C43)CC#C)CC2)=O)=C1C NRZSWYSJFMDDAN-UHFFFAOYSA-N 0.000 claims 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
QVRZRNRGZLATEA-UHFFFAOYSA-N 5-benzyl-2-[(5-methyl-1h-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one Chemical compound N1C=NC(CN2C(C3=C(N(C4=CC=CC=C43)CC=3C=CC=CC=3)CC2)=O)=C1C QVRZRNRGZLATEA-UHFFFAOYSA-N 0.000 claims 1
JPVWBONUBZPXKW-UHFFFAOYSA-N 6-methyl-2-[(5-methyl-1h-imidazol-4-yl)methyl]-4,5-dihydro-3h-azepino[4,3-b]indol-1-one Chemical compound N1C=NC(CN2C(C3=C(N(C4=CC=CC=C43)C)CCC2)=O)=C1C JPVWBONUBZPXKW-UHFFFAOYSA-N 0.000 claims 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
150000008052 alkyl sulfonates Chemical class 0.000 claims 1
125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
239000010452 phosphate Substances 0.000 claims 1
ZUGVYAVSPOHDQS-UHFFFAOYSA-N pyrido[4,3-b]indol-1-one Chemical compound C1=CC=CC2=C3C(=O)N=CC=C3N=C21 ZUGVYAVSPOHDQS-UHFFFAOYSA-N 0.000 claims 1
229940095064 tartrate Drugs 0.000 claims 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract description 7
230000000694 effects Effects 0.000 abstract description 5
230000003389 potentiating effect Effects 0.000 abstract description 5
102000035037 5-HT3 receptors Human genes 0.000 abstract description 3
108091005477 5-HT3 receptors Proteins 0.000 abstract description 3
206010047700 Vomiting Diseases 0.000 abstract description 3
239000005557 antagonist Substances 0.000 abstract description 3
208000028017 Psychotic disease Diseases 0.000 abstract description 2
150000003951 lactams Chemical class 0.000 abstract description 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 135
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 126
239000000203 mixture Substances 0.000 description 99
239000000243 solution Substances 0.000 description 96
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 94
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
238000003818 flash chromatography Methods 0.000 description 68
239000007787 solid Substances 0.000 description 67
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 59
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 56
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 55
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 47
239000003921 oil Substances 0.000 description 41
235000019198 oils Nutrition 0.000 description 41
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 40
239000000543 intermediate Substances 0.000 description 40
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 39
239000000284 extract Substances 0.000 description 39
239000000725 suspension Substances 0.000 description 36
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 35
235000019441 ethanol Nutrition 0.000 description 34
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 32
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 30
239000012312 sodium hydride Substances 0.000 description 30
229910000104 sodium hydride Inorganic materials 0.000 description 30
239000000377 silicon dioxide Substances 0.000 description 27
239000011541 reaction mixture Substances 0.000 description 24
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 23
239000006185 dispersion Substances 0.000 description 22
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
239000000047 product Substances 0.000 description 20
239000003826 tablet Substances 0.000 description 19
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
238000006243 chemical reaction Methods 0.000 description 18
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
239000012458 free base Substances 0.000 description 14
239000002904 solvent Substances 0.000 description 14
229960000583 acetic acid Drugs 0.000 description 13
238000004458 analytical method Methods 0.000 description 13
238000007796 conventional method Methods 0.000 description 13
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
238000001816 cooling Methods 0.000 description 12
125000006239 protecting group Chemical group 0.000 description 12
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 11
238000010992 reflux Methods 0.000 description 11
AHHFSTCSFJWTEF-UHFFFAOYSA-N 4-(chloromethyl)-5-methyl-1-tritylimidazole Chemical compound CC1=C(CCl)N=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 AHHFSTCSFJWTEF-UHFFFAOYSA-N 0.000 description 10
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
239000003054 catalyst Substances 0.000 description 10
238000000746 purification Methods 0.000 description 10
229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
235000017557 sodium bicarbonate Nutrition 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 9
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
235000011087 fumaric acid Nutrition 0.000 description 8
235000019359 magnesium stearate Nutrition 0.000 description 8
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
239000000843 powder Substances 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 7
239000002253 acid Substances 0.000 description 7
239000000443 aerosol Substances 0.000 description 7
150000002148 esters Chemical class 0.000 description 7
238000001704 evaporation Methods 0.000 description 7
238000009472 formulation Methods 0.000 description 7
238000007429 general method Methods 0.000 description 7
238000005984 hydrogenation reaction Methods 0.000 description 7
239000008101 lactose Substances 0.000 description 7
239000011976 maleic acid Substances 0.000 description 7
LFBMTFQWORFEHB-UHFFFAOYSA-N 2,3,4,5-tetrahydropyrido[4,3-b]indol-1-one Chemical compound N1C2=CC=CC=C2C2=C1CCNC2=O LFBMTFQWORFEHB-UHFFFAOYSA-N 0.000 description 6
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
239000002585 base Substances 0.000 description 6
230000008020 evaporation Effects 0.000 description 6
239000000706 filtrate Substances 0.000 description 6
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 6
239000000463 material Substances 0.000 description 6
239000012074 organic phase Substances 0.000 description 6
238000003756 stirring Methods 0.000 description 6
239000006188 syrup Substances 0.000 description 6
235000020357 syrup Nutrition 0.000 description 6
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 6
TXHAMOKKTTZMKG-UHFFFAOYSA-N 2-[(5-methyl-1-tritylimidazol-4-yl)methyl]-4,5-dihydro-3h-pyrido[4,3-b]indol-1-one Chemical compound CC1=C(CN2C(C=3C4=CC=CC=C4NC=3CC2)=O)N=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 TXHAMOKKTTZMKG-UHFFFAOYSA-N 0.000 description 5
GLHMAFAXJJECMG-UHFFFAOYSA-N 5-methyl-3,4-dihydro-2h-pyrido[4,3-b]indol-1-one Chemical compound C12=CC=CC=C2N(C)C2=C1C(=O)NCC2 GLHMAFAXJJECMG-UHFFFAOYSA-N 0.000 description 5
239000004338 Dichlorodifluoromethane Substances 0.000 description 5
229920002472 Starch Polymers 0.000 description 5
230000010933 acylation Effects 0.000 description 5
238000005917 acylation reaction Methods 0.000 description 5
239000008346 aqueous phase Substances 0.000 description 5
XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 5
239000002775 capsule Substances 0.000 description 5
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 5
235000019404 dichlorodifluoromethane Nutrition 0.000 description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
239000012442 inert solvent Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
239000003755 preservative agent Substances 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
239000008107 starch Substances 0.000 description 5
229940032147 starch Drugs 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 5
229940029284 trichlorofluoromethane Drugs 0.000 description 5
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 5
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 4
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 4
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
239000005642 Oleic acid Substances 0.000 description 4
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000003377 acid catalyst Substances 0.000 description 4
230000002378 acidificating effect Effects 0.000 description 4
230000029936 alkylation Effects 0.000 description 4
238000005804 alkylation reaction Methods 0.000 description 4
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
150000004945 aromatic hydrocarbons Chemical class 0.000 description 4
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
229910052801 chlorine Inorganic materials 0.000 description 4
239000000796 flavoring agent Substances 0.000 description 4
235000019634 flavors Nutrition 0.000 description 4
239000006260 foam Substances 0.000 description 4
239000012362 glacial acetic acid Substances 0.000 description 4
150000008282 halocarbons Chemical class 0.000 description 4
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
229910052740 iodine Inorganic materials 0.000 description 4
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 4
239000010410 layer Substances 0.000 description 4
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 4
229910052753 mercury Inorganic materials 0.000 description 4
239000004533 oil dispersion Substances 0.000 description 4
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
229910000027 potassium carbonate Inorganic materials 0.000 description 4
230000008569 process Effects 0.000 description 4
239000008213 purified water Substances 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
238000007363 ring formation reaction Methods 0.000 description 4
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
238000010626 work up procedure Methods 0.000 description 4
DGJKKXAFDOWIQI-UHFFFAOYSA-N 4-(chloromethyl)-n,n,5-trimethylimidazole-1-sulfonamide Chemical compound CN(C)S(=O)(=O)N1C=NC(CCl)=C1C DGJKKXAFDOWIQI-UHFFFAOYSA-N 0.000 description 3
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 3
239000002841 Lewis acid Substances 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
238000005903 acid hydrolysis reaction Methods 0.000 description 3
230000009471 action Effects 0.000 description 3
239000000654 additive Substances 0.000 description 3
229910052794 bromium Inorganic materials 0.000 description 3
239000000872 buffer Substances 0.000 description 3
229910002091 carbon monoxide Inorganic materials 0.000 description 3
239000000460 chlorine Substances 0.000 description 3
239000003086 colorant Substances 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
238000000354 decomposition reaction Methods 0.000 description 3
238000001035 drying Methods 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000008187 granular material Substances 0.000 description 3
229910052736 halogen Inorganic materials 0.000 description 3
150000002367 halogens Chemical class 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000011630 iodine Substances 0.000 description 3
150000007517 lewis acids Chemical class 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
JFCHSQDLLFJHOA-UHFFFAOYSA-N n,n-dimethylsulfamoyl chloride Chemical compound CN(C)S(Cl)(=O)=O JFCHSQDLLFJHOA-UHFFFAOYSA-N 0.000 description 3
150000002923 oximes Chemical class 0.000 description 3
HBEQXAKJSGXAIQ-UHFFFAOYSA-N oxopalladium Chemical compound [Pd]=O HBEQXAKJSGXAIQ-UHFFFAOYSA-N 0.000 description 3
229910003445 palladium oxide Inorganic materials 0.000 description 3
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
229910000029 sodium carbonate Inorganic materials 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
229910052717 sulfur Inorganic materials 0.000 description 3
239000000829 suppository Substances 0.000 description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 3
239000011592 zinc chloride Substances 0.000 description 3
235000005074 zinc chloride Nutrition 0.000 description 3
125000006594 (C1-C3) alkylsulfony group Chemical group 0.000 description 2
PNCQSQGMGBIKRP-UHFFFAOYSA-N 1-[(5-methyl-1h-imidazol-4-yl)methyl]piperidine-2,4-dione Chemical compound N1=CNC(CN2C(CC(=O)CC2)=O)=C1C PNCQSQGMGBIKRP-UHFFFAOYSA-N 0.000 description 2
OOEPMQUADWCBCH-UHFFFAOYSA-N 2-[[3-(methoxymethyl)-5-methylimidazol-4-yl]methyl]-5-methyl-3,4-dihydropyrido[4,3-b]indol-1-one Chemical compound COCN1C=NC(C)=C1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 OOEPMQUADWCBCH-UHFFFAOYSA-N 0.000 description 2
125000006304 2-iodophenyl group Chemical group [H]C1=C([H])C(I)=C(*)C([H])=C1[H] 0.000 description 2
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
ADCUCAMWCWNHJA-UHFFFAOYSA-N 4-(chloromethyl)-1-tritylimidazole Chemical compound C1=NC(CCl)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 ADCUCAMWCWNHJA-UHFFFAOYSA-N 0.000 description 2
OXOVPJWOAZQOHI-UHFFFAOYSA-N 4-(chloromethyl)-n,n-dimethyl-5-propylimidazole-1-sulfonamide Chemical compound CCCC1=C(CCl)N=CN1S(=O)(=O)N(C)C OXOVPJWOAZQOHI-UHFFFAOYSA-N 0.000 description 2
PMYOGCJNAPXFIY-UHFFFAOYSA-N 4-formyl-n,n-dimethyl-5-propylimidazole-1-sulfonamide Chemical compound CCCC1=C(C=O)N=CN1S(=O)(=O)N(C)C PMYOGCJNAPXFIY-UHFFFAOYSA-N 0.000 description 2
KUYOAXVRVDNQPV-UHFFFAOYSA-N 4-methoxy-1-[(5-methyl-1-tritylimidazol-4-yl)methyl]-2,3-dihydropyridin-6-one Chemical compound C1CC(OC)=CC(=O)N1CC1=C(C)N(C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C=N1 KUYOAXVRVDNQPV-UHFFFAOYSA-N 0.000 description 2
RMXWUHZMUSTECR-UHFFFAOYSA-N 5-(phenylmethoxymethyl)-3,4-dihydro-2h-pyrido[4,3-b]indol-1-one Chemical compound O=C1NCCC2=C1C1=CC=CC=C1N2COCC1=CC=CC=C1 RMXWUHZMUSTECR-UHFFFAOYSA-N 0.000 description 2
BXFUGXGCSXOZAJ-UHFFFAOYSA-N 5-ethyl-3,4-dihydro-2h-pyrido[4,3-b]indol-1-one Chemical compound C12=CC=CC=C2N(CC)C2=C1C(=O)NCC2 BXFUGXGCSXOZAJ-UHFFFAOYSA-N 0.000 description 2
RHHLGJBTMKMCPV-UHFFFAOYSA-N 5-methyl-2h-pyrido[4,3-b]indol-1-one Chemical compound C1=CNC(=O)C2=C1N(C)C1=CC=CC=C12 RHHLGJBTMKMCPV-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
238000006237 Beckmann rearrangement reaction Methods 0.000 description 2
239000004215 Carbon black (E152) Substances 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
208000018522 Gastrointestinal disease Diseases 0.000 description 2
206010021518 Impaired gastric emptying Diseases 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
DKNPRRRKHAEUMW-UHFFFAOYSA-N Iodine aqueous Chemical compound [K+].I[I-]I DKNPRRRKHAEUMW-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
229920000388 Polyphosphate Polymers 0.000 description 2
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
239000002168 alkylating agent Substances 0.000 description 2
229940100198 alkylating agent Drugs 0.000 description 2
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
235000019700 dicalcium phosphate Nutrition 0.000 description 2
208000010643 digestive system disease Diseases 0.000 description 2
238000007907 direct compression Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000011049 filling Methods 0.000 description 2
239000010419 fine particle Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
239000007789 gas Substances 0.000 description 2
208000018685 gastrointestinal system disease Diseases 0.000 description 2
208000001288 gastroparesis Diseases 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
230000008570 general process Effects 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
150000002430 hydrocarbons Chemical class 0.000 description 2
150000002431 hydrogen Chemical class 0.000 description 2
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
150000002576 ketones Chemical class 0.000 description 2
239000007788 liquid Substances 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
HFBHDROMBUQLIP-UHFFFAOYSA-N n,n,5-trimethyl-4-(trimethylsilyloxymethyl)imidazole-1-sulfonamide Chemical compound CN(C)S(=O)(=O)N1C=NC(CO[Si](C)(C)C)=C1C HFBHDROMBUQLIP-UHFFFAOYSA-N 0.000 description 2
YCXGBKXNHZLDMI-UHFFFAOYSA-N n,n,5-trimethyl-4-[(5-methyl-1-oxo-3,4-dihydropyrido[4,3-b]indol-2-yl)methyl]imidazole-1-sulfonamide Chemical compound CN(C)S(=O)(=O)N1C=NC(CN2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)=C1C YCXGBKXNHZLDMI-UHFFFAOYSA-N 0.000 description 2
FKBRJZVYJBNUIY-UHFFFAOYSA-N n,n,5-trimethyl-4-[[2-(1-methylindol-2-yl)ethylamino]methyl]imidazole-1-sulfonamide Chemical compound CN(C)S(=O)(=O)N1C=NC(CNCCC=2N(C3=CC=CC=C3C=2)C)=C1C FKBRJZVYJBNUIY-UHFFFAOYSA-N 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
229910000510 noble metal Inorganic materials 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
150000002940 palladium Chemical class 0.000 description 2
RDNZDMDLRIQQAX-UHFFFAOYSA-N piperidine-2,4-dione Chemical compound O=C1CCNC(=O)C1 RDNZDMDLRIQQAX-UHFFFAOYSA-N 0.000 description 2
229910052697 platinum Inorganic materials 0.000 description 2
239000001205 polyphosphate Substances 0.000 description 2
235000011176 polyphosphates Nutrition 0.000 description 2
229920000137 polyphosphoric acid Polymers 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
239000012429 reaction media Substances 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
208000011117 substance-related disease Diseases 0.000 description 2
229940124530 sulfonamide Drugs 0.000 description 2
238000006277 sulfonation reaction Methods 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
150000003512 tertiary amines Chemical class 0.000 description 2
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
238000005550 wet granulation Methods 0.000 description 2
DVQYFYUODSFBFS-UHFFFAOYSA-N (1-tritylimidazol-4-yl)methanol Chemical compound C1=NC(CO)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 DVQYFYUODSFBFS-UHFFFAOYSA-N 0.000 description 1
UBHDUFNPQJWPRQ-UHFFFAOYSA-N (5-methyl-1h-imidazol-3-ium-4-yl)methanol;chloride Chemical compound Cl.CC=1NC=NC=1CO UBHDUFNPQJWPRQ-UHFFFAOYSA-N 0.000 description 1
125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 description 1
RASWJSHXBNEYDY-BTJKTKAUSA-N (z)-but-2-enedioic acid;2-[(1,5-dimethylimidazol-4-yl)methyl]-5-methyl-3,4-dihydropyrido[4,3-b]indol-1-one Chemical compound OC(=O)\C=C/C(O)=O.N1=CN(C)C(C)=C1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 RASWJSHXBNEYDY-BTJKTKAUSA-N 0.000 description 1
VUZCFMZRDGYNSG-BTJKTKAUSA-N (z)-but-2-enedioic acid;2-[(5-methyl-1h-imidazol-4-yl)methyl]-5-prop-2-enyl-3,4-dihydropyrido[4,3-b]indol-1-one Chemical compound OC(=O)\C=C/C(O)=O.N1C=NC(CN2C(C3=C(N(C4=CC=CC=C43)CC=C)CC2)=O)=C1C VUZCFMZRDGYNSG-BTJKTKAUSA-N 0.000 description 1
QPKNDWSYGJXCEO-BTJKTKAUSA-N (z)-but-2-enedioic acid;2-[(5-methyl-1h-imidazol-4-yl)methyl]-5-propan-2-yl-3,4-dihydropyrido[4,3-b]indol-1-one Chemical compound OC(=O)\C=C/C(O)=O.O=C1C=2C3=CC=CC=C3N(C(C)C)C=2CCN1CC=1N=CNC=1C QPKNDWSYGJXCEO-BTJKTKAUSA-N 0.000 description 1
PAQMEHQYNACSEU-BTJKTKAUSA-N (z)-but-2-enedioic acid;5-(cyclopentylmethyl)-2-[(5-methyl-1h-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one Chemical compound OC(=O)\C=C/C(O)=O.N1C=NC(CN2C(C3=C(N(C4=CC=CC=C43)CC3CCCC3)CC2)=O)=C1C PAQMEHQYNACSEU-BTJKTKAUSA-N 0.000 description 1
ZTHVDSYBNXUCPJ-BTJKTKAUSA-N (z)-but-2-enedioic acid;5-cyclopentyl-2-[(5-methyl-1h-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one Chemical compound OC(=O)\C=C/C(O)=O.N1C=NC(CN2C(C3=C(N(C4=CC=CC=C43)C3CCCC3)CC2)=O)=C1C ZTHVDSYBNXUCPJ-BTJKTKAUSA-N 0.000 description 1
XCPGTDZMQXRLAW-BTJKTKAUSA-N (z)-but-2-enedioic acid;5-methyl-2-[(5-methyl-1h-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one Chemical compound OC(=O)\C=C/C(O)=O.N1C=NC(CN2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)=C1C XCPGTDZMQXRLAW-BTJKTKAUSA-N 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
PBEUMTWYLAGXEX-UHFFFAOYSA-N 1-[(5-methyl-1h-imidazol-4-yl)methyl]-4-(2-methyl-2-phenylhydrazinyl)-2,3-dihydropyridin-6-one Chemical compound C=1C=CC=CC=1N(C)NC(CC1)=CC(=O)N1CC=1N=CNC=1C PBEUMTWYLAGXEX-UHFFFAOYSA-N 0.000 description 1
MWOODERJGVWYJE-UHFFFAOYSA-N 1-methyl-1-phenylhydrazine Chemical compound CN(N)C1=CC=CC=C1 MWOODERJGVWYJE-UHFFFAOYSA-N 0.000 description 1
MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
ZPOFFMPKLVBLRL-UHFFFAOYSA-N 2,2,2-trifluoro-n-[2-(1-methylindol-2-yl)ethyl]acetamide Chemical compound C1=CC=C2N(C)C(CCNC(=O)C(F)(F)F)=CC2=C1 ZPOFFMPKLVBLRL-UHFFFAOYSA-N 0.000 description 1
PXYDYCFAXVGSNA-UHFFFAOYSA-N 2-(1-methylindol-2-yl)ethanamine Chemical compound C1=CC=C2N(C)C(CCN)=CC2=C1 PXYDYCFAXVGSNA-UHFFFAOYSA-N 0.000 description 1
ZJRMSUNJKHZGPW-UHFFFAOYSA-N 2-[[1-(methoxymethyl)-5-methylimidazol-4-yl]methyl]-5-methyl-3,4-dihydropyrido[4,3-b]indol-1-one Chemical compound COCN1C=NC(CN2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)=C1C ZJRMSUNJKHZGPW-UHFFFAOYSA-N 0.000 description 1
NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
BCCREUFCSIMJFS-UHFFFAOYSA-N 2-hydroxy-n-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]acetamide Chemical compound OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1 BCCREUFCSIMJFS-UHFFFAOYSA-N 0.000 description 1
WSLMOORTNOTZCO-UHFFFAOYSA-N 2-iodo-n-methylaniline Chemical compound CNC1=CC=CC=C1I WSLMOORTNOTZCO-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
ZHIDLFGPDBGBLX-UHFFFAOYSA-N 3-(1h-imidazol-2-ylmethyl)-2,3,4,4a-tetrahydrocarbazol-1-one Chemical class C1C(C2=CC=CC=C2N=2)C=2C(=O)CC1CC1=NC=CN1 ZHIDLFGPDBGBLX-UHFFFAOYSA-N 0.000 description 1
JNMKJQUPZRMPIE-UHFFFAOYSA-N 3-methylpyrido[4,3-b]indol-1-one Chemical compound CC=1C=C2N=C3C=CC=CC3=C2C(N=1)=O JNMKJQUPZRMPIE-UHFFFAOYSA-N 0.000 description 1
125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
PKRJDTRWPVLSHE-UHFFFAOYSA-N 4-(hydroxymethyl)-n,n,5-trimethylimidazole-1-sulfonamide Chemical compound CN(C)S(=O)(=O)N1C=NC(CO)=C1C PKRJDTRWPVLSHE-UHFFFAOYSA-N 0.000 description 1
RZGVDQPSCBOBDQ-UHFFFAOYSA-N 4-(hydroxymethyl)-n,n-dimethyl-5-propylimidazole-1-sulfonamide Chemical compound CCCC1=C(CO)N=CN1S(=O)(=O)N(C)C RZGVDQPSCBOBDQ-UHFFFAOYSA-N 0.000 description 1
UTLSUROOFACDBW-UHFFFAOYSA-N 4-methoxy-2,3-dihydro-1h-pyridin-6-one Chemical compound COC1=CC(=O)NCC1 UTLSUROOFACDBW-UHFFFAOYSA-N 0.000 description 1
DUTCFYSYEZIRIM-UHFFFAOYSA-N 5-(chloromethyl)-4-methyl-1,3-oxazole Chemical compound CC=1N=COC=1CCl DUTCFYSYEZIRIM-UHFFFAOYSA-N 0.000 description 1
XZRDRAUKLDOVIH-UHFFFAOYSA-N 5-(cyclopentylmethyl)-2-[(5-methyl-1h-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one Chemical compound N1C=NC(CN2C(C3=C(N(C4=CC=CC=C43)CC3CCCC3)CC2)=O)=C1C XZRDRAUKLDOVIH-UHFFFAOYSA-N 0.000 description 1
JCFIPPLALIRIET-UHFFFAOYSA-N 5-(cyclopentylmethyl)-3,4-dihydro-2h-pyrido[4,3-b]indol-1-one Chemical compound O=C1NCCC2=C1C1=CC=CC=C1N2CC1CCCC1 JCFIPPLALIRIET-UHFFFAOYSA-N 0.000 description 1
RXLGOHHFTLYPCI-FJOGWHKWSA-N 5-benzyl-2-[(5-methyl-1h-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one;(z)-but-2-enedioic acid;hydrate Chemical compound O.OC(=O)\C=C/C(O)=O.N1C=NC(CN2C(C3=C(N(C4=CC=CC=C43)CC=3C=CC=CC=3)CC2)=O)=C1C RXLGOHHFTLYPCI-FJOGWHKWSA-N 0.000 description 1
WMSYJNVNJATAIS-UHFFFAOYSA-N 5-benzyl-3,4-dihydro-2h-pyrido[4,3-b]indol-1-one Chemical compound O=C1NCCC2=C1C1=CC=CC=C1N2CC1=CC=CC=C1 WMSYJNVNJATAIS-UHFFFAOYSA-N 0.000 description 1
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
MKPQNXCDWBSEFV-UHFFFAOYSA-N 5-methyl-2-[(4-methyl-1,3-oxazol-5-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one Chemical compound N1=COC(CN2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)=C1C MKPQNXCDWBSEFV-UHFFFAOYSA-N 0.000 description 1
HUVUZHZJTLINGI-UHFFFAOYSA-N 5-methyl-2-[(5-methyl-1h-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one;sulfuric acid Chemical compound OS(O)(=O)=O.N1C=NC(CN2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)=C1C HUVUZHZJTLINGI-UHFFFAOYSA-N 0.000 description 1
CEMLEXILBQLXAX-UHFFFAOYSA-N 5-methyl-2-[(5-methyl-1h-imidazol-4-yl)methyl]pyrido[4,3-b]indol-1-one Chemical compound N1C=NC(CN2C(C=3C4=CC=CC=C4N(C)C=3C=C2)=O)=C1C CEMLEXILBQLXAX-UHFFFAOYSA-N 0.000 description 1
HERSBFYGOLITAA-UHFFFAOYSA-N 5-propan-2-yl-3,4-dihydro-2h-pyrido[4,3-b]indol-1-one Chemical compound C12=CC=CC=C2N(C(C)C)C2=C1C(=O)NCC2 HERSBFYGOLITAA-UHFFFAOYSA-N 0.000 description 1
AYSGWEZTYITIHQ-UHFFFAOYSA-N 5-propyl-1h-imidazole-4-carbaldehyde Chemical compound CCCC=1NC=NC=1C=O AYSGWEZTYITIHQ-UHFFFAOYSA-N 0.000 description 1
RMNNQLHYNXIIEU-UHFFFAOYSA-N 6-methyl-2,3,4,5-tetrahydroazepino[4,3-b]indol-1-one Chemical compound C1CCNC(=O)C2=C1N(C)C1=CC=CC=C12 RMNNQLHYNXIIEU-UHFFFAOYSA-N 0.000 description 1
JCBYXNSOLUVGTF-UHFFFAOYSA-N 6-piperazin-1-yl-11h-benzo[b][1,4]benzodiazepine Chemical compound C1CNCCN1C1=NC2=CC=CC=C2NC2=CC=CC=C12 JCBYXNSOLUVGTF-UHFFFAOYSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
229910015900 BF3 Inorganic materials 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
LZAVXZOBGRPQAN-BTJKTKAUSA-N C(\C=C/C(=O)O)(=O)O.N1C=CC2=CC(=CC=C12)C(=O)N Chemical compound C(\C=C/C(=O)O)(=O)O.N1C=CC2=CC(=CC=C12)C(=O)N LZAVXZOBGRPQAN-BTJKTKAUSA-N 0.000 description 1
125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
QILYOVOVCQPYFP-UHFFFAOYSA-N CC1=C(N=CN1C(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)CN1CC2=C(NC=3C=CC=CC23)CC1 Chemical compound CC1=C(N=CN1C(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)CN1CC2=C(NC=3C=CC=CC23)CC1 QILYOVOVCQPYFP-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
YIIMEMSDCNDGTB-UHFFFAOYSA-N Dimethylcarbamoyl chloride Chemical compound CN(C)C(Cl)=O YIIMEMSDCNDGTB-UHFFFAOYSA-N 0.000 description 1
241000792859 Enema Species 0.000 description 1
241000400611 Eucalyptus deanei Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
240000006711 Pistacia vera Species 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical group OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
GELXFVQAWNTGPQ-UHFFFAOYSA-N [N].C1=CNC=N1 Chemical group [N].C1=CNC=N1 GELXFVQAWNTGPQ-UHFFFAOYSA-N 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
229910001508 alkali metal halide Inorganic materials 0.000 description 1
150000008045 alkali metal halides Chemical class 0.000 description 1
229910000102 alkali metal hydride Inorganic materials 0.000 description 1
150000008046 alkali metal hydrides Chemical class 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
125000004849 alkoxymethyl group Chemical group 0.000 description 1
230000002152 alkylating effect Effects 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000003420 antiserotonin agent Substances 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
125000005002 aryl methyl group Chemical group 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
HRQGCQVOJVTVLU-UHFFFAOYSA-N bis(chloromethyl) ether Chemical compound ClCOCCl HRQGCQVOJVTVLU-UHFFFAOYSA-N 0.000 description 1
230000037396 body weight Effects 0.000 description 1
BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000001722 carbon compounds Chemical class 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000007810 chemical reaction solvent Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
LADPCMZCENPFGV-UHFFFAOYSA-N chloromethoxymethylbenzene Chemical compound ClCOCC1=CC=CC=C1 LADPCMZCENPFGV-UHFFFAOYSA-N 0.000 description 1
125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229960001380 cimetidine Drugs 0.000 description 1
AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
238000004040 coloring Methods 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
150000004292 cyclic ethers Chemical class 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
ISQVBYGGNVVVHB-UHFFFAOYSA-N cyclopentylmethanol Chemical compound OCC1CCCC1 ISQVBYGGNVVVHB-UHFFFAOYSA-N 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
238000007598 dipping method Methods 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
UZZWBUYVTBPQIV-UHFFFAOYSA-N dme dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
150000002084 enol ethers Chemical class 0.000 description 1
210000001353 entorhinal cortex Anatomy 0.000 description 1
PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
239000002024 ethyl acetate extract Substances 0.000 description 1
UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
238000000605 extraction Methods 0.000 description 1
XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
229960001596 famotidine Drugs 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
206010016766 flatulence Diseases 0.000 description 1
238000005187 foaming Methods 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
239000002815 homogeneous catalyst Substances 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
229910000042 hydrogen bromide Inorganic materials 0.000 description 1
238000007327 hydrogenolysis reaction Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
238000001802 infusion Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
VTLNPNNUIJHJQB-UHFFFAOYSA-N loxtidine Chemical compound CN1N=C(CO)N=C1NCCCOC1=CC=CC(CN2CCCCC2)=C1 VTLNPNNUIJHJQB-UHFFFAOYSA-N 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000028161 membrane depolarization Effects 0.000 description 1
230000015654 memory Effects 0.000 description 1
229950002475 mesilate Drugs 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000036651 mood Effects 0.000 description 1
BCSWFTJJDOFVGP-UHFFFAOYSA-N n-(4-methyl-2,3-dihydrocyclopenta[b]indol-1-ylidene)hydroxylamine Chemical compound C12=CC=CC=C2N(C)C2=C1C(=NO)CC2 BCSWFTJJDOFVGP-UHFFFAOYSA-N 0.000 description 1
JQXKMSYCFYGWMG-UHFFFAOYSA-N n-[2-[1-(dimethylsulfamoyl)-5-methylimidazol-4-yl]ethyl]-2,2,2-trifluoro-n-(1-methylindol-2-yl)acetamide Chemical compound CN(C)S(=O)(=O)N1C=NC(CCN(C(=O)C(F)(F)F)C=2N(C3=CC=CC=C3C=2)C)=C1C JQXKMSYCFYGWMG-UHFFFAOYSA-N 0.000 description 1
ATKOQLGBAKPAAF-UHFFFAOYSA-N n-[[1-(dimethylsulfamoyl)-5-methylimidazol-4-yl]methyl]-2,2,2-trifluoro-n-[2-(3-iodo-1-methylindol-2-yl)ethyl]acetamide Chemical compound CN(C)S(=O)(=O)N1C=NC(CN(CCC=2N(C3=CC=CC=C3C=2I)C)C(=O)C(F)(F)F)=C1C ATKOQLGBAKPAAF-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000010004 neural pathway Effects 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
229960004872 nizatidine Drugs 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
229960000381 omeprazole Drugs 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
230000037361 pathway Effects 0.000 description 1
125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
208000011906 peptic ulcer disease Diseases 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
125000003884 phenylalkyl group Chemical group 0.000 description 1
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
238000006303 photolysis reaction Methods 0.000 description 1
230000015843 photosynthesis, light reaction Effects 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
238000003825 pressing Methods 0.000 description 1
YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
239000005297 pyrex Substances 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
QBERHIJABFXGRZ-UHFFFAOYSA-M rhodium;triphenylphosphane;chloride Chemical compound [Cl-].[Rh].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QBERHIJABFXGRZ-UHFFFAOYSA-M 0.000 description 1
229960003320 roxatidine Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
238000005055 short column chromatography Methods 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000002731 stomach secretion inhibitor Substances 0.000 description 1
239000006190 sub-lingual tablet Substances 0.000 description 1
201000009032 substance abuse Diseases 0.000 description 1
231100000736 substance abuse Toxicity 0.000 description 1
150000003890 succinate salts Chemical class 0.000 description 1
JEYKZWRXDALMNG-UHFFFAOYSA-N sufotidine Chemical compound CN1N=C(CS(C)(=O)=O)N=C1NCCCOC1=CC=CC(CN2CCCCC2)=C1 JEYKZWRXDALMNG-UHFFFAOYSA-N 0.000 description 1
229950002504 sufotidine Drugs 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
238000005694 sulfonylation reaction Methods 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
229950004288 tosilate Drugs 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
238000001665 trituration Methods 0.000 description 1
210000001186 vagus nerve Anatomy 0.000 description 1
229910052720 vanadium Inorganic materials 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychiatry (AREA)
Pharmacology & Pharmacy (AREA)
Neurology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Pyrrole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Cephalosporin Compounds (AREA)

SK4044-91A 1987-09-03 1991-12-23 Tricyclic lactam compounds, pharmaceutical compositions comprising same and their use SK404491A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB878720695A GB8720695D0 (en)	1987-09-03	1987-09-03	Chemical compounds
GB888819382A GB8819382D0 (en)	1988-08-15	1988-08-15	Lactame derivatives

Publications (1)

Publication Number	Publication Date
SK404491A3 true SK404491A3 (en)	2000-12-11

Family

ID=26292675

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK4044-91A SK404491A3 (en)	1987-09-03	1991-12-23	Tricyclic lactam compounds, pharmaceutical compositions comprising same and their use

Country Status (15)

Country	Link
EP (1)	EP0306323B1 (de)
AT (1)	ATE111910T1 (de)
AU (1)	AU613662B2 (de)
CY (1)	CY1789A (de)
CZ (1)	CZ404491A3 (de)
DE (1)	DE3851597T2 (de)
ES (1)	ES2060655T3 (de)
GB (1)	GB2209335B (de)
HK (1)	HK75591A (de)
HU (1)	HU211843A9 (de)
IE (1)	IE61669B1 (de)
IL (1)	IL87658A (de)
NZ (1)	NZ226032A (de)
PH (1)	PH25493A (de)
SK (1)	SK404491A3 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4672117A (en) *	1985-09-16	1987-06-09	American Home Products Corporation	Antipsychotic gamma-carbolines
US4636563A (en) *	1985-09-16	1987-01-13	American Home Products Corporation	Antipsychotic γ-carbolines
DE3822792C2 (de) *	1987-07-11	1997-11-27	Sandoz Ag	Neue Verwendung von 5HT¶3¶-Antagonisten
US4985422A (en) *	1988-04-27	1991-01-15	Glaxo Group Limited	Lactam derivatives
HU207078B (en) *	1988-08-02	1993-03-01	Glaxo Group Ltd	Process for producing lactam derivatives and pharmaceutical compositions comprising such compounds
AU631131B2 (en) *	1988-08-02	1992-11-19	Glaxo Group Limited	Lactam derivatives
JPH02167280A (ja) *	1988-08-15	1990-06-27	Glaxo Group Ltd	ラクタム誘導体
US4997831A (en) *	1988-09-01	1991-03-05	Glaxo Group Limited	Lactam derivatives
GB8820650D0 (en) *	1988-09-01	1988-10-05	Glaxo Group Ltd	Medicaments
GB8820653D0 (en) *	1988-09-01	1988-10-05	Glaxo Group Ltd	Medicaments
GB8820651D0 (en) *	1988-09-01	1988-10-05	Glaxo Group Ltd	Medicaments
EP0377238A1 (de) *	1988-12-22	1990-07-11	Duphar International Research B.V	Annelierte Indolo(3,2-c)-lactame
US5223625A (en) *	1988-12-22	1993-06-29	Duphar International Research B.V.	Annelated indolo [3,2,-C]lactams
GB8904552D0 (en) *	1989-02-28	1989-04-12	Glaxo Group Ltd	Chemical process
GB8904551D0 (en) *	1989-02-28	1989-04-12	Glaxo Group Ltd	Chemical compounds
HU204049B (en) *	1989-02-28	1991-11-28	Glaxo Group Ltd	Process for producing lactam derivatives and pharmaceutical compositions comprising same
EP0392663A1 (de) *	1989-03-13	1990-10-17	Ono Pharmaceutical Co., Ltd.	Ein Carbolin-Derivat als 5-HT3-Rezeptor-Antagonist
ZA902794B (en) *	1989-04-18	1991-04-24	Duphar Int Res	New 3-n substituted carbamoyl-indole derivatives
AU631632B2 (en)	1989-04-21	1992-12-03	Novartis Ag	Therapeutic use of 5-ht3 receptor antagonists
US5530008A (en) *	1989-04-21	1996-06-25	Sandoz Ltd.	Use of 5-HT3 receptor antagonists in treating panic disorders or obsessive compulsive disorders
GB8913646D0 (en) *	1989-06-14	1989-08-02	Glaxo Group Ltd	Chemical compounds
GB8917557D0 (en) *	1989-08-01	1989-09-13	Glaxo Group Ltd	Medicaments
US5276050A (en) *	1989-08-01	1994-01-04	Glaxo Group Limited	Medicaments
US5180728A (en) *	1989-09-25	1993-01-19	Fujisawa Pharmaceutical Company, Ltd.	Pyrimidoindole derivatives and processes for preparation thereof
GB8928208D0 (en) *	1989-12-13	1990-02-14	Glaxo Group Ltd	Medicaments
GB8928837D0 (en) *	1989-12-21	1990-02-28	Beecham Group Plc	Pharmaceuticals
GB9011469D0 (en) *	1990-05-23	1990-07-11	Glaxo Group Ltd	Chemical process
US5102889B1 (en) *	1990-09-27	1993-05-11		2-(4-piperidinyl)-1h-pyrido(4,3-b)indol-1-ones and related compounds
US5229517A (en) *	1990-09-27	1993-07-20	Hoechst-Roussel Pharmaceuticals Incorporated	2-(4-Piperindinyl)-1H-pyrido[4,3-B]indol-1-ones and related compounds
US5189041A (en) *	1990-11-16	1993-02-23	Syntex (U.S.A.) Inc.	Tricyclic 5-ht3 receptor antagonists
GB9721139D0 (en)	1997-10-07	1997-12-03	Glaxo Group Ltd	Medicaments
WO2001058869A2 (en) *	2000-02-11	2001-08-16	Bristol-Myers Squibb Company	Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
WO2003061657A1 (en)	2002-01-18	2003-07-31	Aryx Therapeutics	5-ht3 receptor antagonists and methods of use
RU2544856C2 (ru)	2008-01-25	2015-03-20	Сергей Олегович Бачурин	НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP2253316B1 (de)	2009-05-20	2013-08-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Serotonin-5-HT3-Rezeptorantagonisten zur Verwendung bei der Behandlung oder Prävention einer Innenohr-Pathologie mit Vestibularisdefiziten
CN102458400B (zh)	2009-05-20	2014-10-08	国立健康与医学研究所	用于治疗病灶性前庭功能障碍的血清素5-ht3受体拮抗剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU583343B2 (en) *	1985-01-23	1989-04-27	Glaxo Group Limited	Heterocyclic compounds
AU631131B2 (en) *	1988-08-02	1992-11-19	Glaxo Group Limited	Lactam derivatives
HU204049B (en) *	1989-02-28	1991-11-28	Glaxo Group Ltd	Process for producing lactam derivatives and pharmaceutical compositions comprising same

1988
- 1988-09-02 NZ NZ226032A patent/NZ226032A/en unknown
- 1988-09-02 GB GB8820736A patent/GB2209335B/en not_active Expired - Lifetime
- 1988-09-02 IE IE266988A patent/IE61669B1/en not_active IP Right Cessation
- 1988-09-02 DE DE3851597T patent/DE3851597T2/de not_active Expired - Lifetime
- 1988-09-02 EP EP88308135A patent/EP0306323B1/de not_active Expired - Lifetime
- 1988-09-02 AU AU21742/88A patent/AU613662B2/en not_active Expired
- 1988-09-02 ES ES88308135T patent/ES2060655T3/es not_active Expired - Lifetime
- 1988-09-02 AT AT88308135T patent/ATE111910T1/de not_active IP Right Cessation
- 1988-09-02 PH PH37492A patent/PH25493A/en unknown
- 1988-09-02 IL IL8765888A patent/IL87658A/en not_active IP Right Cessation
1991
- 1991-09-26 HK HK755/91A patent/HK75591A/xx not_active IP Right Cessation
- 1991-12-23 CZ CS914044A patent/CZ404491A3/cs unknown
- 1991-12-23 SK SK4044-91A patent/SK404491A3/sk unknown
1995
- 1995-06-28 HU HU95P/P00522P patent/HU211843A9/hu unknown
- 1995-10-20 CY CY178995A patent/CY1789A/en unknown

Also Published As

Publication number	Publication date
IL87658A (en)	1994-06-24
DE3851597D1 (de)	1994-10-27
ATE111910T1 (de)	1994-10-15
GB8820736D0 (en)	1988-10-05
DE3851597T2 (de)	1995-01-26
EP0306323A3 (en)	1990-07-18
IE882669L (en)	1989-03-03
NZ226032A (en)	1991-12-23
AU613662B2 (en)	1991-08-08
PH25493A (en)	1991-07-24
CY1789A (en)	1995-10-20
GB2209335A (en)	1989-05-10
HK75591A (en)	1991-10-04
IE61669B1 (en)	1994-11-16
HU211843A9 (en)	1995-12-28
IL87658A0 (en)	1989-02-28
EP0306323A2 (de)	1989-03-08
CZ404491A3 (en)	1993-04-14
ES2060655T3 (es)	1994-12-01
AU2174288A (en)	1989-03-09
EP0306323B1 (de)	1994-09-21
GB2209335B (en)	1991-05-29

Publication	Publication Date	Title
SK404491A3 (en)	2000-12-11	Tricyclic lactam compounds, pharmaceutical compositions comprising same and their use
DK169922B1 (da)	1995-04-03	Substituerede (imidazol-4-yl)methylpyrido-, og -azepino-, indolonderivater, fremgangsmåde til fremstilling deraf samt farmaceutiske præparater indeholdende derivaterne
DE69620241T2 (de)	2002-10-02	Gonadotropin releasing hormon- antagonisten
US4997841A (en)	1991-03-05	Indole derivatives
US6294555B1 (en)	2001-09-25	1-[(1-Substituted-4-piperidinyl)methyl]-4-piperidine derivative, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
PT95899A (pt)	1991-09-13	Processo para a preparacao de derivados indole
HUT74090A (en)	1996-11-28	Indole derivatives, process for producing them and pharmaceutical compositions containing them
CA2242579A1 (en)	1997-07-17	Benzimidzolyl neuropeptide y receptor antagonists
JPH0256485A (ja)	1990-02-26	ラクタム誘導体
EP0344015A2 (de)	1989-11-29	Tetracyclische Ketone
JPH03200786A (ja)	1991-09-02	ラクタム誘導体
EP0307145A1 (de)	1989-03-15	Ketonderivate
US5360800A (en)	1994-11-01	Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
US5008272A (en)	1991-04-16	Lactam derivatives
JPH0249772A (ja)	1990-02-20	イミダゾール誘導体
JPS63277665A (ja)	1988-11-15	ケトン誘導体
JPH01308277A (ja)	1989-12-12	ケトン誘導体
JPH01258673A (ja)	1989-10-16	ケトン誘導体
JP2941702B2 (ja)	1999-08-30	５‐ｈｔ３レセプターにおいて５‐ｈｔの作用に拮抗するラクタム誘導体を含む医薬組成物
RU2067980C1 (ru)	1996-10-20	Производные лактама и фармацевтическая композиция, являющаяся антагонистом 5-окситраптамина /5-нт/ на 5- нт3 -рецепторах или их физиологически приемлемые соли и соловаты
EP0345956B1 (de)	1994-03-16	Tricyclische Ketone
FI89484B (fi)	1993-06-30	Foerfarande foer framstaellning av terapeutiskt aktiva tetrahydro-2-/(imidazol-4-yl)metyl/pyrido(4,3-b)indol- och azepino-/4,3-b/indol-1-oner
DD291765A5 (de)	1991-07-11	Verfahren zur herstellung von lactamderivaten
JPWO1999055674A1 (ja)	2002-11-05	１−［（１−置換−４−ピペリジニル）メチル］−４−ピペリジン誘導体、その製造方法、それを含有する医薬組成物および該化合物の中間体